Diabetes
Diabetes study shines spotlight on lifestyle interventions
A new study assesses real-world lifestyle interventions to help delay or prevent the costly chronic disease that affects nearly 26 million Americans.
Treatment for diabetes and depression improves both, researchers say
Patients simultaneously treated for both Type 2 diabetes and depression improve medication compliance and significantly improve blood sugar and depression levels compared to patients receiving usual care, according to a new study.
Exogenous Glucagon-Like Peptide-1 for Hyperglycemia in Critically Ill Patients
OBJECTIVE: To review literature evaluating the safety and efficacy of exogenous glucagon-like peptide-1 (GLP-1) for hyperglycemia in critically ill patients.
DATA SOURCES: PubMed was queried (inception to September 3, 2011), using the search term glucagon-like peptide-1. The search was limited to studies published in English and conducted in humans. Regular and late-breaking abstracts from the American Diabetes Association Scientific Sessions in 2009 and 2010 were also searched using the same search term.
Glycemic Control and Preventive Care Measures of Indigent Diabetes Patients Within a Pharmacist-Managed Insulin Titration Program vs Standard Care
BACKGROUND: Studies assessing pharmacist-led services have noted positive clinical diabetes outcomes; however, studies assessing pharmacist impact on glycemic control through insulin titration and adherence to American Diabetes Association (ADA) preventive care measures in an indigent population are limited.
OBJECTIVE: To assess the impact of a pharmacist-managed insulin titration program compared to standard medical care on glycemic control and preventive care measures in an indigent population with diabetes.
Clinical Efficacy and Safety of Once-Weekly Glucagon-Like Peptide-1 Agonists in Development for Treatment of Type 2 Diabetes Mellitus in Adults
OBJECTIVE: To review pharmacologic, pharmacokinetic, efficacy, and safety data of once-weekly glucagon-like peptide-1 (GLP-1) agonists exenatide long-acting release (LAR), albiglutide, and taspoglutide in treatment of type 2 diabetes mellitus (T2DM).
DATA SOURCES: A MEDLINE search (1966-August 2011) was conducted using the following key words: type 2 diabetes mellitus, glucagon-like peptide-1 agonists once weekly, glucagon-like peptide-1 agonists, exenatide LAR, albiglutide, and taspoglutide.
Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women's Health Initiative [Original Investigation]
Background This study investigates whether the incidence of new-onset diabetes mellitus (DM) is associated with statin use among postmenopausal women participating in the Women's Health Initiative (WHI).
[Articles] Effectiveness of diabetes and hypertension management by rural primary health-care workers (Behvarz workers) in Iran: a nationally representative observational study
SummaryBackgroundNon-communicable diseases and their risk factors are leading causes of disease burden in Iran and other middle-income countries. Little evidence exists for whether the primary health-care system can effectively manage non-communicable diseases and risk factors at the population level. Our aim was to examine the effectiveness of the Iranian rural primary health-care system (the Behvarz system) in the management of diabetes and hypertension, and to assess whether the effects depend on the number of health-care workers in the community.